Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Canakinumab - Novartis

Drug Profile

Canakinumab - Novartis

Alternative Names: ACZ-885; Anti-IL-1 beta monoclonal antibody; Antibody A; Ilaris

Latest Information Update: 19 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer Charite - Universitatsmedizin Berlin; Novartis; Triemli hospital; University Hospital Tubingen; University Hospital Zurich
  • Class Anti-inflammatories; Antihyperglycaemics; Antineoplastics; Antirheumatics; Cardiovascular therapies; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Interleukin 1 beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Juvenile rheumatoid arthritis; Inflammation; Familial Mediterranean fever; Familial autosomal dominant periodic fever
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Adult-onset Still's disease; Cryopyrin-associated periodic syndromes; Familial autosomal dominant periodic fever; Familial Mediterranean fever; Gouty arthritis; Juvenile rheumatoid arthritis; Peroxisomal disorders
  • Preregistration Cardiovascular disorders
  • Phase III Behcet's syndrome; Non-small cell lung cancer
  • Phase II Abdominal aortic aneurysm; Atherosclerosis; Malignant melanoma; Osteoarthritis; Peripheral arterial occlusive disorders; Pulmonary sarcoidosis; Schnitzler syndrome; Sickle cell anaemia
  • No development reported Chronic obstructive pulmonary disease
  • Discontinued Asthma; Diabetic retinopathy; Polymyalgia rheumatica; Rheumatoid arthritis; Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 20 Nov 2018 Novartis plans a phase Ib trial for Breast cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in December 2018 (Parenteral) (NCT03742349)
  • 25 Oct 2018 Novartis announces intention to submit regulatory applications for Non-small cell lung cancer in 2021 (Novartis pipeline, February 2018)
  • 19 Oct 2018 Adverse events data from the phase III CLUSTER trial in Familial Mediterranean fever presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting (ACR/ARHP-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top